1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A856A08ED6DCCC8B65257FD50028B5E4
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-benchmarking-professional-biopharmaceutical-medical-education-groups-structures-resources-activities?opendocument
18
19opendocument
20107.23.176.162
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Medical Education

Benchmarking Professional Medical Education Excellence: Structures, Resources and Activities to Optimize Large Biopharmaceutical Education Groups

ID: 5419


Features:

15 Info Graphics

30 Data Graphics

250+ Metrics

10 Narratives


Pages/Slides: 57


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Benchmarking Professional Medical Education Excellence: Structures, Resources and Activities to Optimize Large Biopharmaceutical Education Groups"

STUDY OVERVIEW

Medical education programs serve as an important platform for large biopharmaceutical organizations to inform physicians and other health care professionals about new products and therapies. While this remains as true today as it was in the past, recent regulations have tempered the sponsorship of some medical education programs by biopharmaceutical companies, as well as some third-party providers of such services.

To succeed in this challenging environment, organizations need to re-examine their education programs to ensure they have the proper structure, staffing and activities.

Best Practices, LLC undertook benchmarking research to investigate emerging Medical Education trends regarding funding and program types at large life sciences companies. The study also informs Medical Affairs and Medical Education leaders on the proper size, resourcing, and structure for this function or group at large companies.


KEY TOPICS

Medical Education Group Structure and Activities Performed
Funding Channels Utilized by Medical Education Groups
Staffing Benchmarks for Medical Education Groups
Benchmarks for Medical Education Resources, Investment Allocation and Budget Allocation by Region and Program Type
Trends in Grants to Professional Societies/Associations for Accredited and Non-Accredited Education Programs
Future Trends in Medical Education Staffing and Investment

KEY METRICS

Global Investment Level Dedicated to Medical Education Function
Internal Medical Education Funding Sources
Budget Allocation by Region and Program Type
Distribution Channels Utilized to Support Accredited and Non-Accredited Education
Medical Education Funding Allocations
Total Number of Full Time Equivalent Employees (FTEs) Working in Global Professional Medical Education Organization
Budget Per Full Time Equivalent Employee (FTE)
Average Span of Control (Number of staff per manager)
Regional FTE Allocation
Programs per FTE
Budget per Program

SAMPLE KEY FINDINGS

Benchmark Companies Rely Heavily On Outsourcing: Large companies rely on outsourcing for developing and deploying medical education programs. They outsource 53% of medical education program development to vendors, while 58% of companies use vendors for program deployment and delivery.

METHODOLOGY

Best Practices, LLC engaged 11 leaders supporting medical education at 9 leading life sciences and medical device companies. More than 50% of participants are at the level of director/senior director and around 27% of participants are managers. More than 70% of participants are from the US.


Industries Profiled:
Biotech; Pharmaceutical; Medical Device; Health Care


Companies Profiled:
Allergan; Astellas; AstraZeneca; Baxter; Boehringer Ingelheim; Daiichi Sankyo; Medtronic; Pfizer; Siemens Medical


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.